Gene · 135152
Papers1,850
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 1,850
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| UGT2B10 is the Major UDP-Glucuronosyltransferase 2B Isoform Involved in the Metabolism of Lamotrigine and is Implicated in the Drug-Drug Interaction with Valproic Acid. | AAPS J | 2024 | 39322784 | PubTator, text mining | PubMed |
| Flucloxacillin instantly decreases serum levels of valproic acid: A case report. | Br J Clin Pharmacol | 2024 | 39254135 | PubTator, text mining | PubMed |
| Extracellular vesicles as the next-generation modulators of pharmacokinetics and pharmacodynamics of medications and their potential as adjuvant therapeutics. | Clin Transl Med | 2024 | 39167024 | PubTator, text mining | PubMed |
| Microbial metabolism marvels: a comprehensive review of microbial drug transformation capabilities. | Gut Microbes | 2024 | 39150897 | PubTator, text mining | PubMed |
| Pharmacokinetic drug-drug interactions of JBPOS0101 mediated by cytochrome P450 3A4 and UDP-glucuronosyltransferases. | Clin Transl Sci | 2024 | 39034448 | PubTator, text mining | PubMed |
Identification of the human Cytochrome P450 enzymes (P450s) responsible for metabolizing infigratinib to its pharmacologically active Metabolites, BHS697, and CQM157, and assessment of their in vitro inhibition of P450s and UDP-glucuronosyltransferases (UGTs). | Biochem Pharmacol | 2024 | 38914316 | PubTator, text mining | PubMed |
| Avapritinib Carries the Risk of Drug Interaction via Inhibition of UDP-Glucuronyltransferase (UGT) 1A1. | Curr Drug Metab | 2024 | 38803186 | PubTator, text mining | PubMed |
| Metabolism characterization and toxicity of N-hydap, a marine candidate drug for lung cancer therapy by LC-MS method. | Nat Prod Bioprospect | 2024 | 38771401 | PubTator, text mining | PubMed |
| Inhibition of human UDP-glucuronosyltransferase enzyme by entrectinib: Implications for drug-drug interactions. | Chem Biol Interact | 2024 | 38677539 | PubTator, text mining | PubMed |
| Identification of Bromophenols' glucuronidation and its induction on UDP- glucuronosyltransferases isoforms. | Ecotoxicol Environ Saf | 2024 | 38581907 | PubTator, text mining | PubMed |
| Human UDP-glucuronosyltransferase 1As catalyze aristolochic acid D O-glucuronidation to form a lesser nephrotoxic glucuronide. | J Ethnopharmacol | 2024 | 38548118 | PubTator, text mining | PubMed |
| Statins Ticagrelor and Rhabdomyolysis: A Coincidence or a Drug Interaction? | J Lipid Atheroscler | 2024 | 38299164 | PubTator, text mining | PubMed |
| Harnessing Sulforaphane Potential as a Chemosensitizing Agent: A Comprehensive Review. | Cancers (Basel) | 2024 | 38254735 | PubTator, text mining | PubMed |
| Cytotoxic Effects of Major and Emerging Mycotoxins on HepaRG Cells and Transcriptomic Response after Exposure of Spheroids to Enniatins B and B1. | Toxins (Basel) | 2024 | 38251270 | PubTator, text mining | PubMed |
| The Multifaceted Roles of NRF2 in Cancer: Friend or Foe? | Antioxidants (Basel) | 2024 | 38247494 | PubTator, text mining | PubMed |
| Identification of novel F2-isoprostane metabolites by specific UDP-glucuronosyltransferases. | Redox Biol | 2024 | 38211441 | PubTator, text mining | PubMed |
| A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir. | Clin Pharmacokinet | 2024 | 38177893 | PubTator, text mining | PubMed |
| The potential impact of CYP and UGT drug-metabolizing enzymes on brain target site drug exposure. | Drug Metab Rev | 2024 | 38126313 | PubTator, text mining | PubMed |
| Study of the ketohexokinase inhibitor PF-06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy. | Clin Transl Sci | 2024 | 38108609 | PubTator, text mining | PubMed |
| A comprehensive analysis of the expression, immune infiltration, prognosis and partial experimental validation of CHST family genes in gastric cancer. | Transl Oncol | 2024 | 38101175 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/135152/papers?page=5